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To explore the relevance of T-follicular-helper (Tfh) and pathogenic peripheral-helper T-cells 3 
(Tph) in promoting ectopic  lymphoid structures (ELS) and B-cell MALT lymphomas (MALT-4 
L) in Sjögren’s syndrome (SS) patients. 5 
Methods: Salivary gland (SG) biopsies with matched peripheral blood were collected from 4 6 
centres across the EU. Transcriptomic (microarray and quantitative PCR) analysis, FACS T-cell 7 
immunophenotyping with intracellular cytokine detection, multicolor immune-fluorescence 8 
microscopy and in situ hybridization were performed to characterize lesional and circulating Tfh 9 
and Tph-cells. SG-organ cultures were used to investigate functionally the blockade of T-cell co-10 
stimulatory pathways on key pro-inflammatory cytokine production. 11 
Results:  12 
Transcriptomic analysis in SG identified Tfh-signature, IL-21 and the ICOS costimulatory 13 
pathway as the most upregulated genes in ELS+ SS patients, with parotid MALT-L displaying a 14 
400-folds increase in IL-21 mRNA. Peripheral CD4+CXCR5+PD1+ICOS+ Tfh-like cells were 15 
significantly expanded in ELS+ SS patients, were the main producers of IL-21, and closely 16 
correlated with circulating IgG and reduced complement C4. In the SG, lesional 17 
CD4+CD45RO+ICOS+PD1+ cells selectively infiltrated ELS+ tissues and were aberrantly 18 
expanded in parotid MALT-L. In ELS+ SG and MALT-L parotids, conventional 19 
CXCR5+CD4+PD1+ICOS+Foxp3- Tfh-cells and a uniquely expanded population of CXCR5-20 
CD4+PD1hiICOS+Foxp3- Tph-cells displayed frequent IL-21/IFN-γ double-production but poor 21 
IL-17 expression. Finally, ICOS blockade in ex vivo SG organ cultures significantly reduced the 22 
production of IL-21 and inflammatory cytokines IL-6, IL-8, and TNF-α.  23 
Conclusions: 1 
Overall, these findings highlight Tfh and Tph-cells, IL-21 and the ICOS co-stimulatory pathway 2 


























Introduction  1 
Sjogren’s syndrome (SS) is characterized by lymphocytic infiltration of the exocrine glands, 2 
mainly the lacrimal and salivary glands (SG) [1]. The pathogenic role of B-cells in SS is an 3 
hallmark of the disease including the presence of circulating autoantibodies, alterations in 4 
peripheral B-cell sub-populations [2], B-cells predominance in advanced SG lesions [3] and the 5 
increased risk of developing non-Hodgkin B-cell mucosa-associated lymphoid tissue (MALT)-6 
lymphoma in SS [4]. In around 30-40% of SS patients, B-cell infiltrates forming in minor (labial) 7 
SG are organized in ectopic GC [5]; follicles formed by aggregates of segregated B and T-cells 8 
endowed with a FDC network. These structures, also known as ectopic lymphoid structures 9 
(ELS), function as niches for auto-reactive B-cells [6].  10 
In physiological GC responses, efficient T-cell-dependent antigen-driven B-cell response in vivo 11 
depends on the development of functional GCs which require T-follicular helper (Tfh) cells [7–12 
9], where Tfh-secreted IL-21 is a critical factor for B-cell maturation [7,10–12]. Tfh-cells are 13 
highly specialized CD4+ memory T-helper cells, characterized by high expression of the CXC-14 
motif chemokine receptor 5 (CXCR5), the inducible T-cell co-stimulator (ICOS) molecule, the 15 
co-inhibitory molecule programmed cell death protein 1 (PD-1) and the transcription factor Bcl6 16 
[13]. Tfh-cells migrate to the B-cell follicle in response to the follicular dendritic cell (FDC-) 17 
produced CXCR5 ligand, CXCL13 [14]. At the border with and inside the GC, Tfh-cells interact 18 
with B-cells through ICOS and its ligand, ICOSL, releasing high amount of IL-21 [15,16]. Given 19 
their fundamental role as mediators of B-cell activation and antibody production, it is not 20 
surprising that Tfh-cells together with IL-21 have been linked to autoimmune diseases 21 
characterized by a B-cell hyper-activation and dysregulated GC response, including SS [17,18]. 22 
Interestingly, recent work described alternative IL-21-producing Tfh-like cells (also designated 23 
“pathogenic T peripheral helper cells or Tph”) as able to localize at inflammatory sites, such as 24 
rheumatoid arthritis (RA) synovium, in the absence of CXCR5 expression [19]. Tph cells lack 1 
prototypic Tfh markers like CXCR5 and Bcl6 but expresses high levels of IL-21 and CD40L. 2 
Similarly to canonical Tfh, Tph-cells isolated from inflamed tissue [19,20] can drive the 3 
differentiation of  B-cells into antibody-secreting cells in vitro [19].  4 
To date, the relevance of Tfh and Tph-cells in the development of SG ELS and evolution to 5 
MALT-L in SS has not been clarified. To address this question, we performed a comprehensive 6 
investigation in matched SG histology, transcriptomic and lesional/peripheral T-cell 7 
immunophenotyping validated in samples from 4 different centres which identified a subset of 8 
Tfh and Tph-cells expressing high levels of IL-21 and/or IL-21/IFN-γ under the control of ICOS 9 














MATERIALS AND METHODS 1 
Patients sample collection  2 
Blood and labial SG biopsies were collected after informed consent from patients with SS (n=83) 3 
fulfilling the 2002 revised criteria of the American-European Consensus Group [21], with non-4 
specific chronic sialadenitis (NSCS) (n=65) and from healthy donors (HD) (n=12). Sample 5 
collection from 4 European cohorts was approved by ethics committees: REC 05/Q0702/1-6 
Rheumatology/Oral medicine clinic-QMUL, 13/WA/0392-University Hospitals Birmingham-7 
NHS Foundation Trust, Harmonics 4683 (14/9/2017)-Sapienza University of Rome, 8 
MEMORAT-University of Pisa. SS parotids (n=15) with low-grade MALT-L and parotid 9 
adenocarcinoma (n=10) were obtained from the Guy’s Hospital Oral Pathology. MALT-L were 10 
diagnosed histologically by the presence of halos of monocytoid B-cells infiltrating 11 
epimyoepithelial islands and by VDJ PCR for the heavy chain Ig genes [22] for clonal 12 
populations.  13 
 14 
Patient and Public Involvement 15 
There were no funds or time allocated for PPI so we were unable to involve patients.  Patients 16 
were invited to help us developing our dissemination strategy. 17 
 18 
Immunohistochemistry (IHC) and immunofluorescence (IF) on SG tissue 19 
After deparaffinization, formalin-fixed paraffin-embedded sections were incubated with antigen 20 
retrieval solution pH6 (Dako) in pressure cooker (for CD20, CD138, CD3, CD68, CD4, 21 
CD45RO, PD1, ICOS, BCL6), or with proteinase-K (Dako) (for CD21). After appropriate 22 
blocking steps and primary antibody (Table S1) staining, slides were incubated with HRP-23 
conjugated secondary antibody and developed with DAB (Dako). For IF, slides were incubated 1 
with the relevant secondary antibodies (Table S1) prior to DAPI nuclear counterstaining. Images 2 
were captured using Olympus BX61 Motorized Microscope or confocal microscope (Leica 3 
DM5500Q). 4 
 5 
Flow cytometry  6 
Flow-cytometry analysis was performed on 52 frozen PBMCs prior thawing. Egressed cells from 7 
1 parotid MALT-L and PBMCs were stimulated with PMA (50ng/mL), ionomycyn (750ng/mL), 8 
Brefeldin-A (10µg/mL) in RPMI complete (RPMI+10% fetal bovine serum) medium, for 3 9 
hours.  Cells were stained using Zombie Aqua Live/Dead kit (Biolegend) for 15 minutes, washed 10 
and incubated for 10 minutes with human Fc TruStain FcX (Biolegend). Cells were stained for 11 
surface antigens, fixed, permeabilized (fixation-permeabilization buffer; eBioscience) and 12 
stained for intracellular cytokines. Antibodies used are listed in Table S2. Cells were acquired 13 
using an LSR Fortessa II (BD Biosciences) flow cytometer and analysed with FlowJo V10 14 
software.  15 
 16 
Whole-genome microarray analysis and quantitative gene expression profiling in human 17 
SG tissue 18 
For whole-genome microarray, biotin-labeled amplified complementary RNA (cRNA) from total 19 
SG RNA was amplified according to the MessageAmp Premier Protocol (ThermoFisher). cRNA 20 
(20µg) was fragmented for hybridization on Affymetrix Human Genome U133 Plus 2.0 21 
GeneChip arrays. Data capture and quality assessments were performed with the GeneChip 22 
Operating Software tool and data analysis with R using affy, frma and dependent packages to 23 
generate a scaled gene expression matrix.  eBayes R package was used for statistical analysis of 1 
differential transcript expression and gene signature analysis was performed using the GSVA 2 
package (Gene Set Variation Analysis) [23]  and a collection of established gene signatures.  A 3 
list of genes defining the gene signatures are listed in Table S3. Targeted quantitative TaqMan 4 
RT-PCR was performed as previously described [24]; primers and probes are listed in Table S4. 5 
 6 
RNAScope fluorescence in situ hybridization (FISH) for IL-21 RNA 7 
In situ hybridization for IL-21 RNA (NM_021803.3) was performed following manufacturer’s 8 
instructions (Advanced Cell Diagnostics) on optimally prepared paraffin SG tissue. RNAscope 9 
probe Hs-IL21 (code 401251) was applied for 2 h at 40 °C and the signal was detected using 10 
Alexa Fluor™ 488 Tyramide Reagent (ThermoFisher, code B40953). Slides were then washed in 11 
PBS and stained for ICOS (Abcam, code Ab105227) and CD4 (Dako, code M7310) overnight. 12 
After incubation with secondary antibodies, slides were DAPI counterstained and mounted in 13 
ProLong Gold (ThermoFisher, code P36930). Slides were digitized using NanoZoomer S60 slide 14 
scanner (Hamamatsu Photonics). DapB (code 310043) and Hs-POLR2A (code 310451) were 15 
used as negative and positive control probes, respectively.  16 
 17 
ICOS blockade in vitro assay 18 
SG organ cultures were performed in complete RPMI medium. Each SG lobule was cut in half 19 
and each half incubated with either anti-ICOS blocking antibody (clone JTA-009) [25,26] or its 20 
isotype control (10µg/mL), for 3 days and MALT-L for 24 hours, due to the different time for 21 
cell egression. Multiple samples from one parotid MALT-L parotidectomy and 3 SS patient 22 
labial SG (2 to 8 lobules per patient) were tested. All supernatants were collected and frozen 1 
before analysis. 2 
 3 
Protein detection in sera and supernatants 4 
IL-21 levels in serum was quantified using an IL-21 ELISA (Biolegend, code 433804) following 5 
manufacturer’s instructions. In the organ culture supernatant, cytokines levels were screened 6 
with Proteome profiler human XL cytokine array kit (R&D, code ARY022B) in line with 7 
manufacturer’s instruction. Cytokines were quantified using customized multiplex liquid phase 8 
immunoassay (Biolegend, LegendPlex) and/or with specific ELISA assays (IL-6 and IL-8, 9 
Biolegend, 430504 and 431504 respectively).  10 
 11 
Statistical analysis 12 
Differences in quantitative variables were analyzed by the Mann Whitney U-test when 13 
comparing 2 groups and by Kruskal-Wallis with Dunn’s post-test correction when comparing 14 
multiple groups. χ2 test with Yates’ correction when required or Fisher’s exact test when 15 
appropriate were used to evaluate associations of qualitative variables in the different groups. 16 
Spearman's rank analysis was performed for non-parametric variable correlations. All the 17 
statistical analyses were performed using GraphPad Prism version 7 for Windows (GraphPad 18 





Results  1 
Expansion of circulating IL-21 producing T-follicular helper cells identifies SS patients 2 
with systemic immune activation and higher salivary gland infiltration  3 
We first analyzed circulating IL-21 level and the frequency of IL-21 production in conventional 4 
Tfh (CXCR5+PD1+ICOS+) and the recently-described Tph (CXCR5-PD1hi ICOS+) in SS patients 5 
and their correlation with clinical, immunological and histopathological activity. Patient 6 

















Table 1: Summary of the patient characteristics 1 





Gender  F/M 75/ 8 57/ 8 11/ 1 
Age in years  
mean [median] (SD) 54 [55] (14.0)  55 [56] (13.3) 43 [44] (7.4) 
 
Primary/ Secondary  
Sjogren’s Syndrome 
 
Disease duration in years  




5.9 [3] (6.0)  
 
 
5.1 [3] (5.6) 
 
ESSDAI 
mean [median] (SD) 5.5 [5] (4.9) n/a  
Anti-Ro 
Positive of total 59% 0%  
Anti-La  
Positive of total 35% 0%  
Rheumatoid factor  
Positive of total 51% 11%  
Serum IgG (g/L) 
mean [median] (SD) 15.4 [14.0] (5.8)  11.0 [11.1] (3.7)   
Serum IgA (g/L) 
mean [median] (SD) 2.9 [2.3] (1.8) 2.8 [2.5] (2.4)  
Serum IgM (g/L) 
mean [median] (SD) 1.5 [1.1] (2.0) 1.3 [1.1] (0.7)  
Serum C3 (g/L) 
mean [median] (SD)  1.2 [1.2] (0.3) 1.5 [1.3] (1.3)  
Serum C4 (g/L) 
mean [median] (SD) 
 
0.2 [0.2] (0.1) 0.3 [0.3] (0.1)  
Lymphocytes count (x109/L) 
mean [median] (SD) 1.6 [1.5] (0.6) 2.2 [2.1] (0.8)  
*conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) other than 1 
Hydroxychloroquine. 2 
 3 
IL-21 serum levels were increased in SS patients in comparison to NSCS patients and healthy 4 
donors (figure 1A), but showed no correlation with ESSDAI or immunological abnormalities 5 
(figure 1B). Also, IL-21 levels did not differ SS patients stratified for extra-glandular 6 
involvement (figure 1C) or ELS (figure S1) in the SG (figure S2A).   7 
Because of the heterogeneity of markers used so far to define Tfh-cells [18] we performed a 8 
comprehensive analysis of Tfh-cell subsets, by using PD-1 and ICOS expression to identify 9 
bona-fide Tfh-cells as CD4+CD25-Foxp3-CXCR5+ICOS+PD-1+ [27], assessing also their 10 
functional capacity to produce IFN-γ, IL-17 and IL-21 (figure S2B).  11 
Circulating CXCR5+CD4+ T-cells were higher in SS patients compared to NSCS (figure S2C), 12 
with no differences in the general CD4+ frequency (figure S2D). More specifically, SS patients 13 
had an expansion of circulating CXCR5+ICOS+PD-1+ activated Tfh-cells (figure 1D-E, S2E, 14 
S2O) which displayed significantly increased IFN-γ, IL-21 and double IL-21/IFN-γ production 15 
in SS patients compared to NSCS (figure 1F). Circulating IL-21-producing CXCR5+ICOS+PD-1+ 16 
(figure 1G-H) but not total CXCR5+ICOS+PD-1+ or IFN-γ producing Tfh-cells (figure S2F-H) 17 
were higher in SS patients with anti-Ro/SSA and anti-La/SSB autoantibodies. Moreover, 18 
circulating IFN-γ+ and IL-21+CXCR5+ICOS+PD-1+ Tfh-cells positively correlated with serum 19 
IgG levels and inversely with complement C4 (figure 1I-L) unlike IL-21/IFN-γ double producers 20 











Next, we investigated whether circulating Tfh-cells could identify SS patients with more 1 
extensive SG infiltration and the presence of SG ELS (figure S1). IL-21, IFN-γ and IL-21/IFN-γ-2 
producing CXCR5+ICOS+PD-1+ Tfh-cells (figure 1O-Q), but also total CXCR5+ICOS+PD-1+ 3 
Tfh-cells (figure S2K) closely correlated with the SG focus score while  circulating 4 
CXCR5+CD4+ T-cells double expressing ICOS+PD-1+ were higher in SS patients with ELS 5 
(figure 1R, S2L-M,P).  6 
We next analysed the recently described population of  T peripheral helper  (Tph) cells [19] 7 
defined as  CXCR5-PD1hiCD4+ T-cells. Although circulating Tph were increased in the blood of 8 
SS patients compared to NSCS, as previously described [28], we did not observe a selective 9 
expansion of Tph in the ELS+ subgroup (figure 1S).  10 
 11 
Transcriptomic analysis of Tfh-cell signature and an increased IL-21 and IL-21R mRNA 12 
expression identify SG tissue with ELS  13 
We next performed transcriptomic analysis of SG tissue comparing ELS+ SS, ELS- SS and 14 
NSCS patients. Unsupervised clustering showed that ELS+ patients clustered differently from 15 
ELS- and NSCS (figure 2A). A supervised analysis, by pre-classifying patients into ELS+, ELS- 16 
and NSCS, gave similar results, showing a clear association between B-cells, plasma cells and 17 
Tfh signatures with the presence of ELS in SG (figure 2B). Gene Set Variation Analysis (GSVA) 18 
score confirmed that B-cell, Tfh-cell and plasma-cell signatures all segregate ELS+ from ELS- 19 
and NCSC patients (figure 2C-E). Upon analyzing the Tfh signature, we identified 4 Tfh-cell 20 
associated genes: CXCR5, ICOS, PDCD1, SH2D1A as most upregulated in ELS+ SS patients 21 
(figure 2F-I). SH2D1A gene encodes for a SLAM-associated protein (SAP) that stabilizes B and 22 
T-cell interaction and is essential for the differentiation of functional Tfh-cells [29]. 23 
Although the IL-21/IL-21R pathway has been implicated in the pathogenesis of SS [30], there is 1 
no available evidence of its implication in ELS development. Thus, we next performed a targeted 2 
gene expression profiling of IL-21 and IL-21R together with other ELS and GC B-cell-related 3 
genes and showed that IL-21 and IL-21R mRNA were significantly increased in the SG of ELS+ 4 
SS compared to ELS- SS and NSCS patients (figure 2J-K). Additionally, IL-21/IL-21R gene 5 
expression levels increased in parallel with the infiltrating CD20+ B-cells, CD3+ T-cells and 6 
CD138+ plasma cells, but not CD68+ macrophages as assessed by IHC (figure 2L-S). 7 
Furthermore, IL-21 mRNA also correlated with genes associated with ELS (LTB, CXCL13) and 8 
functional B-cell activation (BAFF, AICDA, PAX5) (figure 2T-Y). Overall, these data suggest a 9 
role for the IL-21/IL-21R pathway in driving local B-cell activation within ELS in SG. 10 
 11 
PD1+ICOS+CD4+ T-cells infiltrate ELS+ salivary glands, express IL-21 and co-localize with 12 
ectopic B-cell follicles 13 
Sequential double immunofluorescence stainings for memory T-cells (CD4+CD45RO+), 14 
activated-memory T-cells (CD45RO+PD1+) and Tfh-like cells (PD1+ICOS+) in SS SGs 15 
demonstrated a progressive increase in all cell types, but particularly an enrichment in Tfh-like 16 
cells within B-cell follicles in ELS+ (figure 3A-D). Additionally, semi-quantitative assessment 17 
of cell infiltration demonstrated higher levels of PD1+ICOS+ cells in patients with high 18 
infiltration of B-cells (CD20+), T-cells (CD3+) and plasma cells (CD138+), but not macrophages 19 
(CD68+) (figure 3E-H). In situ hybridization for IL-21 mRNA in combination with CD4/ICOS 20 
immunostaining confirmed that IL-21 expression was confined to ICOS+CD4+ T-cells within 21 
ELS (figure 3I and S4). In keeping with this data, infiltrating PD1+ICOS+ T-cell number 22 
positively correlated with IL-21 mRNA expression in SS SG (figure 3J). 23 
Aberrant expansion of IL-21 and ICOS+PD1+BCL6+ infiltrating T-cells in the evolution to 1 
parotid MALT B-cell lymphomas  2 
Uncontrolled B-cell activation and aberrant somatic hypermutation [22] within SS SG can lead 3 
to genetic instability and progression to parotid B-cell MALT-L in around 5% of SS patients [4], 4 
suggesting that lymphomagenesis in SS is partially sustained by T-cell-driven responses, 5 
similarly to gastric MALT-L [31,32], although also extra follicular and T cell-independent 6 
mechanisms are key in neoplastic B cell expansion [4]. Therefore, we assessed IL-21 production 7 
and Tfh-cells infiltration in SS parotids with MALT-L.  First, IL-21 mRNA expression displayed 8 
~400-fold increase in parotid MALT-L compared to control parotids and ~20-fold increase 9 
compared to ELS+ minor SG biopsies (figure 4A-B). MALT-L also showed an expanded 10 
infiltration of activated-memory (CD45RO+PD1+) and Tfh-like T-cells (PD1+ICOS+) to levels 11 
significantly higher compared to ELS+ SS SGs (figure 4C-E).  12 
Of relevance, within parotid MALT-L, ICOS+PD1+ T-cells acquired BCL6, a transcription factor 13 
essential for Tfh-cell differentiation more frequently than in ELS+ minor SG biopsies (figure 4F) 14 
and resided in close proximity to CD20+BCL6+ GC B-cells (figure 4G).  15 
 16 
Unique SG expansion of Tfh and Tph double IL-21/IFN-γ  producers marks the evolution 17 
to ELS and parotid B-cell MALT-L 18 
FACS profiling of T-cell subsets in parotid MALT-L show how IL-21-producing CD4+ Th cells  19 
represented the most expanded CD4+ population accounting for ~30% of the whole lesional 20 
CD4+ T-cells (figure 5A-B); in comparison Th17 cells, known to be involved in ELS formation 21 
[33,34], made up of less than 1% of cytokine-producing CD4+ T-cells within MALT-L. 22 
Interestingly, IL-21+ CD4+ T-cells frequently displayed concomitant production of IFN-γ but not 23 
IL-17, IL-10 or Granzyme-B in both labial SG and parotid MALT-L which clearly distinguish 1 
these cells from CD4+ T-cells infiltrating inflamed human tonsils (figure S3).  2 
Dimensionality reduction analysis (t-SNE), revealed that IL-21 and IFN-γ-producing lesional T-3 
cells in MALT-L fell within both ICOS+ and PD1+ CD4+ T-cells but displayed variable 4 
expression of CXCR5 (figure 5C). Accordingly,  both ICOS (from ~70% to ~90%) and CXCR5 5 
(from ~30% to ~60%) expression were enriched in IL-21-single producers compared to single 6 
IFN-γ or IL-21/IFN-γ-double producers (figure 5D), suggesting that bona fide CD4+CD25-7 
Foxp3-CXCR5+ICOS+PD-1+ Tfh-cells account for most of lesional IL-21 production in parotid 8 
MALT-L. Of interest, the CXCR5- population of CD4+PD-1hi T-cells displayed a phenotype 9 
highly compatible with Tph-cells, with >95% ICOS expression and enriched in both IL-21 and 10 
IFN-γ production (figure 5E). Overall, these data support the hypothesis that the aberrant 11 
expansion of IL-21 and IL-21/IFN-γ-producing ICOS+PD-1+CD4+ T-cells, independently from 12 
CXCR5 expression, represents an important step in ELS maintenance and MALT-L development 13 
in the SG of SS patients. 14 
 15 
Functional ICOS-blockade controls the release of IL-21 and other pro-inflammatory 16 
cytokines in SG organ cultures  17 
Taken together, our data clearly indicate an expansion of ICOS+CD4+ T-cell subsets (both Tfh-18 
like and Tph-like) in SS patients with ELS and MALT-L. Additionally, hierarchical analysis of 19 
co-stimulatory pathways of microarray data identified ICOS-ICOS-L as the most up-regulated 20 
pathway in SG with ELS (figure 6A), supporting a critical role for ICOS. In order to functionally 21 
investigate the importance of this pathway we set up organ cultures using  either ELS+ labial SG 22 
(figure 6B) or parotid MALT-L tissue (figure 6C)  incubated with a blocking, non-depleting anti-23 
ICOS monoclonal antibody (mAb) or its isotype control. In parotid MALT-L tissue treated with 1 
the anti-ICOS mAb, a protein array screening assay on the organ culture supernatant showed 2 
down-modulation of several proteins including IL-8 and IL-6 as also confirmed by ELISA 3 
(figure 6D). Likewise, analysis of minor SG organ culture supernatants showed that incubation 4 
with the anti-ICOS mAb reduced the levels of IL-21, TNF-α, IL-6 and IL-8 (figure 6E) in 5 
comparison to isotype control-treated glands.  6 
Overall, these data confirm that the ICOS-ICOSL pathway is critical for the activation of 7 
















Discussion  1 
Here, we present a comprehensive analysis of peripheral and lesional CD4+ T-cells at different 2 
stages of SG immunopathology in a large cohort of SS patients, a disease in which ectopic GC 3 
have been linked to the progression towards severe extra-glandular manifestations and B-cell 4 
MALT-L [4]. To start with, we reported the first high throughput transcriptomic profiling of 5 
ELS+ and ELS- SG tissues. Microarray analysis identified, using both unsupervised and 6 
supervised cluster analysis, a Tfh-cell signature, IL-21 and the ICOS-costimulatory pathway as 7 
the most upregulated gene clusters in the ELS+ vs ELS- subset of SS patients. Using quantitative 8 
PCR and in situ hybridization on SG tissue we confirmed that IL-21 mRNA was highly 9 
upregulated in SG with ectopic GCs and lesional Tfh-like cells. Strikingly, an aberrant expansion 10 
of infiltrating Tfh-like cells acquiring expression of the key transcription factor BCL6 was 11 
observed in parotid MALT-L, together with a disproportionate upregulation in IL-21 transcripts. 12 
Characterization of T cell infiltration in control parotid was limited by the lack of matched 13 
histology samples with total RNA. These results are of great interest as MALT-L in SS arises 14 
from post-GC B cells with a marginal zone phenotype often bearing a RF+ autoreactive B cell 15 
receptor [35]. Although extra follicular mechanisms are also likely to be involved in neoplastic B 16 
cell expansion, including  B cell receptor cross-linking [36] and aberrant NFkB activation [37] 17 
via engagement of BAFF and Toll-like receptors [4] the evidence of ongoing intra-tumor clonal 18 
diversification and aberrant somatic hypermutation suggest that ectopic GCs play an active role 19 
in supporting B cell lymphomagenesis [22,38]. Deep phenotyping of lesional CD4+ T-cells in 20 
parotid MALT-L by flow cytometry revealed unexpected and highly novel results whereby we 21 
identified two main CD4+ T-cell subsets responsible for IL-21 production. One subset 22 
represented the bona fide Tfh-cells (Foxp3-CXCR5+ ICOS+PD1+) while the other, which 23 
accounted for around 50% of total IL-21 production in parotid MALT-L, shared striking 1 
similarities with the recently described CXCR5-PD1hiICOS+ pathogenic Tph-cells [19]. Although 2 
these results should be interpreted with caution, as FACS analysis was performed on one MALT-3 
L sample, together with transcriptomic and histology data on a larger cohort, our results provide 4 
the first evidence that this subset may be directly implicated in MALT B-cell-lymphomagenesis 5 
being uniquely able to provide proliferative B-cell signals at extra-follicular sites. Additionally, 6 
both Tfh and Tph-like cells in parotid MALT-L and ELS+ SG displayed heterogeneity in 7 
cytokine production with expanded populations of single IL-21, single IFN-γ and double IL-8 
21/IFN-γ producers; it is unclear whether these represent distinct or evolutionary subsets driven 9 
by the local inflammatory milieu but our work prompts further investigation into our 10 
understanding of the heterogeneity and pathogenic properties of the expanding family of Tfh-like 11 
cells [39].  12 
Due to the heterogeneity in marker combinations used to identify peripheral Tfh-cells in SS 13 
patients in previous works [28,40–44], we performed a comprehensive analysis of Tfh-like cell 14 
subsets in peripheral blood matched with SG on the basis of the expression of CXCR5, ICOS 15 
and PD-1 coupled with intracellular cytokine analysis. Our work indicated that circulating 16 
CXCR5+ICOS+PD-1+ Tfh-cells, which represent a partially differentiated state compared to Tfh 17 
in secondary lymphoid organs, but are able to maintain B-cell differentiating functions [45] are 18 
significantly expanded in ELS+ patients. Notably, the expansion of IL-21 producing 19 
CXCR5+ICOS+PD-1+ Tfh subsets positively correlated with SG focus score and these Tfh-cells 20 
were selectively enriched in patients with ELS in the SG biopsies suggesting that IL-21+ Tfh-21 
cells may represent a useful blood biomarker of SG immunopathology.  Additionally, we further 22 
expanded on previous works by showing how circulating CXCR5+ICOS+PD-1+ Tfh subsets 23 
producing high levels of both IL-21 and IFN-γ (including the detection of double IL-21/IFN-1 
γ producers) are selectively enriched in SS patients with anti-Ro/SSA and anti-La/SSB 2 
autoantibodies, positively correlated with IgG levels and negatively with complement C4. 3 
Overall these data support the notion that circulating Tfh in SS patients play an active role in the 4 
autoimmune B-cell dysregulation typical of SS patients as previously suggested [41,42]. These 5 
data also link well with previous work showing that an over expansion of Tfh-cells is associated 6 
with a dysregulation of B-cell dynamics [44] and the production of autoantibodies [46] and that 7 
an expansion of Tfh-cells might lower the selection pressure on GC B-cells, leading to the 8 
emergence of autoreactive B-cells [47]. 9 
 10 
Finally, in addition to identifying IL-21 and ICOS as key pro-inflammatory and co-stimulatory 11 
signals promoting autoreactive B-cell activation and lymphoma progression in SS patients, we 12 
also provide proof-of-concept functional evidence in SG organ cultures that candidates blocking 13 
the ICOS-pathway as a novel therapeutic option in SS. Here we report that an anti-ICOS non-14 
depleting blocking antibody incubated with either ELS+ SG biopsies or parotid MALT-L 15 
induced a drastic down-regulation of IL-21 and other key pro-inflammatory cytokines. These 16 
data are in line with the evidence that ICOS is required for the reciprocal activation of T-cell to 17 
B-cells [48] and that IL-21 expression by Tfh requires the interaction with ICOS-L (which can 18 
also be expressed by SG epithelial cells) [49]. Our results are highly relevant to the recently 19 
completed phase IIa clinical trial with an anti-ICOSL monoclonal antibody in primary SS 20 
(NCT02334306) and will help interpreting the clinical efficacy of targeting the ICOS/ICOSL 21 
costimulatory pathway in SS by prompting the use of patient stratification on the basis of 22 
lesional and/or peripheral Tfh-cell signatures to achieve maximum clinical efficacy.  23 
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Figure 1.  IL-21 and T follicular helper (Tfh) cells in peripheral blood of SS and NSCS patients.  1 
(A) ELISA quantification of IL-21 serum level (pg/mL) from HD (n=12), NSCS (n=37) and SS (n=37). 2 
(B) Correlations of IL-21 serum level (pg/mL) with serum level of IgG, IgM, IgA, C3, C4 and ESSDAI in 3 
NSCS (n=37) and SS (n=37) patients. Spearman and p value are shown for the significant correlation 4 
(IgG, in red). (C) IL-21 serum level (pg/mL) in SS (n=31) according to ESSDAI domains. Box and 5 
whiskers plot show median and 5-95 percentile. Statistical analysis by Kruskal-Wallis-test with Dunn’s 6 
post-test correction for multiple comparison (A).  (D) Average frequencies of Tfh-cell subsets, identified 7 
on the basis of ICOS and PD-1 expression and their frequencies distribution (E) in NSCS (white dots, 8 
n=10) and SS (dark grey dots, n=42). (F) Frequency of IFN-γ+, IL-21+ and IFN-γ+-IL-21+ double 9 
producing cells as percentage of PD-1+ICOS+, gated on CXCR5+CD4+ cells, detected by flow-cytometry 10 
upon PBMC stimulation with PMA and ionomycin. Frequency of IL-21+ cells segregating the SS cohort 11 
for Ro (G) [Ro- (n=17) and Ro+ (n=20)] and La presence (H) [La- (n=27) and La+ (n=10)]. Spearman 12 
correlation of IL-21+ cell (I,J,O), IFN-γ+ (K, L,P) or IL-21+-IFN-γ+ cell frequency (M,N,Q) with IgG 13 
(g/L) and C4 (g/L) serum levels and SG focus score in NSCS (n=10) and SS (n=42) patients. (R) 14 
Frequency of Tfh-cells subsets identified on the basis of ICOS and PD-1 expression in SS cohort 15 
segregated for ELS presence [ELS-, light grey dots (n=17), ELS+, dark grey dots (n=25)]. (S) Frequency 16 
of CXCR5-PD-1hi cells, as percentage of CD4+ cells, in NSCS (n=10) and SS (n=42), and segregating the 17 
SS cohort for the presence of ELS. Statistical analysis by Mann-Whitney t-test in (C), (E), (F), (G), (H), 18 
(R), (S). All graphs represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 19 
Abbreviations: healthy donor (HD), Non Specific Chronic Sialoadenitis (NSCS), Sjogren’s syndrome 20 





Figure 2. Tfh-cell signature and IL-21 expression correlate with lymphocytic infiltration, 1 
ELS formation and GC B-cell genes in Sjogren's syndrome SGs. 2 
(A) Unsupervised whole-genome microarray analysis from SG RNA of NSCS (n=15) and SS 3 
(n=30), segregated for the absence (ELS-, n=15) and the presence of ELS (ELS+, n=15). (B) 4 
Supervised whole-genome microarray analysis of cohort described in (A), with the signature 5 
pathways rank-ordered for expression intensity. (C-E) GSVA for indicated signatures and (F-I) 6 
gene expression intensity comparison of Tfh-cell signature pathway genes (encoding respectively 7 
for CXCR5, ICOS, SAP and PD-1) in NSCS (n=15), ELS- (n=15) and ELS+ (n=15) SG. Linear 8 
regression model statistics. All graphs represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, 9 
****p<0.0001. Real-time PCR expression for IL-21 (J) and IL-21 receptor (IL21-R) (K) on total 10 
RNA from SG biopsies from NSCS (n=37) and SS (n=29) patients, segregated on the basis of 11 
absence (ELS-, n=7) and presence of ELS (ELS+, n=22). Quantification of IL-21 mRNA (L-O) 12 
and IL-21R expression (P-S) in SG tissue biopsies, according to histological semi-quantitative 13 
score (0 to 3) of B (CD20), T (CD3), plasma cells (CD138) and macrophages (CD68). Statistical 14 
analysis by Kruskal-Wallis-test with Dunn’s post-test correction for multiple comparison. (T-Y) 15 
Spearman correlation analysis between IL-21 mRNA in SG and indicated lymphoid and GC B-16 
cell genes. All graphs represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 17 
Abbreviations: Non Specific Chronic Sialoadenitis (NSCS), Sjogren’s syndrome (SS), Ectopic 18 





Figure 3. PD-1+ICOS+CD45RO+CD4+ cells are increased within SG with ELS in SS and 1 
produce IL-21. 2 
(A) Representative immunofluorescence detection of CD4+CD45RO+ (top row), PD1+CD45RO+ 3 
(middle row) and ICOS+PD1+ cells (bottom row) in SG biopsy tissues with ELS. (B-D) 4 
Quantification (mean counts per field, a minimum of 5 random fields) of the double positive 5 
cells for each double immunofluorescence combination in SG biopsy tissues from NSCS (n=8) 6 
and SS (n=12) patients. Images displayed at x20 magnification. (E-H) ICOS+PD1+ cell count 7 
was segregated according to histological semi-quantitative score (0 to 3) of B (CD20), T (CD3) 8 
plasma cells (CD138) and macrophages (CD68). Statistical analysis by Kruskal-Wallis-test with 9 
Dunn’s post-test correction for multiple comparison (B-H). (I) Representative fluorescent in situ 10 
hybridization (FISH) detection of IL-21 RNA, co-stained with CD4 and ICOS in SG biopsy 11 
tissues with ELS. (J) Spearman correlation analysis between SG real-time PCR IL-21 mRNA 12 
expression with ICOS+PD1+ cell count. All graphs represent mean ± SEM. *p<0.05, **p<0.01, 13 
***p<0.001, ****p<0.0001. Abbreviations: Non Specific Chronic Sialoadenitis (NSCS), 14 








Figure 4. Development of parotid MALT lymphomas is associated with elevated SG IL-21 1 
and IL-21R expression. 2 
Real-time PCR expression for IL-21 (A) and IL21-R (B) on RNA extracted from SS labial SG 3 
biopsies with ELS (ELS+, n=22), SS parotid SG MALT-lymphoma (n=15) and parotid 4 
adenocarcinoma (n=10). Quantification (mean counts per field) of (C) CD4+CD45RO+, (D) 5 
PD1+CD45RO+, (E) PD1+ICOS+ cells in SS labial SG biopsies with ELS (ELS+, n=10) and SS 6 
parotid SG MALT-lymphoma (n=7). Mann-Whitney t-test statistics. (F) Mean counts per field of 7 
ICOS+BCL6+ cells between SS parotid SG MALT-lymphoma (n=23), SS labial SG biopsies with 8 
ELS (ELS+, n=21) and tonsils (n=3). Statistical analysis by Kruskal-Wallis-test with Dunn’s 9 
post-test correction for multiple comparisons (A,B,F). (G) Representative immunofluorescence 10 
detection of ICOS+BCL6+ cells relative to B (CD20+) cell aggregates in SG biopsy tissues with 11 
ELS, parotid SG MALT-lymphoma and tonsil. 	12 
 13 
Figure 5. SG inflammation and development of parotid MALT lymphomas is associated 14 
with increased Tfh-cell numbers with increase production of IL-21 and IFN-γ. 15 
(A)  Pie chart showing the cytokines production by T helper (CD4+) cells isolated from parotid 16 
SG MALT-lymphoma (n=1), upon stimulation with PMA and ionomycin and flow-cytometry 17 
analysis. (B) Representative flow-cytometry dot plots for cytokines production by T helper 18 
(CD4+) cells and (C) tSNE plots for indicated markers in T helper (CD4+) cells from parotid SG 19 
MALT-lymphoma. Flow-cytometry gating strategy for the identification of (D) IL-21 and IFN-γ 20 
producing Tfh-cells (identified as CD4+CD25-Foxp3- CXCR5+ICOS+PD-1+) and (E) pathogenic 21 
T peripheral helper cells (identified as CD4+CD25-Foxp3-CXCR5-ICOS+PD-1+) in parotid SG 22 
MALT-lymphoma (n=1). All graphs represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, 23 
****p<0.0001. Abbreviations: Sjogren’s syndrome (SS), Salivary glands (SG), Ectopic 1 
Lymphoid Structure (ELS). 2 
 3 
 4 
Figure 6. The blockade of ICOS-ICOS ligand signaling pathway reduces pro-inflammatory 5 
cytokines level in SG with ELS and MALT-lymphoma organ culture in SS  6 
(A) Ingenuity Pathway Analysis (IPA) of microarray data obtained from the analysis of RNA 7 
extracted from ELS- and ELS+ SG. The orange-colored bars (ICOS-ICOSL, CD28, CD40) show 8 
predicted pathway activation (with positive z-score), while the white bar (OX40 signaling 9 
pathway) indicates a z-score at or very close to 0 and the grey bar (CTLA4) pathways where no 10 
prediction can be made. (B) Schematic representation of a labial minor SG lobule cut 11 
longitudinally in half for the organ culture experiment. (C) Representative histological images 12 
(H&E and IHC for CD20) of inflammatory infiltration in a parotid SG with B-cell Non-Hodgkin 13 
MALT-lymphoma from a SS patient. (D) Multiplex antibody array for cytokine analysis in the 14 
supernatant of a parotid MALT-lymphoma (n=1) organ culture, treated with an anti-ICOS 15 
blockade or its isotype control. The array template (white panel on the left) shows the coordinate 16 
reference of analytes with IL-6 spots highlighted (black circle). Black panels show the arrays 17 
incubated with organ culture supernatants treated with isotype control or anti-ICOS blockade 18 
with white circles around IL-6 spots. ELISA quantification of IL-8 and IL-6 in the supernatants 19 
of MALT-lymphoma organ culture, treated with an anti-ICOS blockade (grey dots) or its isotype 20 
control (white dots). Each dot represents a technical replicate. (E) Levels of TNF-α, IL-21, IL-8 21 
and IL-6 detected in the supernatant of minor SG lobule organ culture, treated with an anti-ICOS 22 
blockade or its isotype control. The same colour dots represent minor SG lobules (from 2 to 8 23 
lobules) from the same SS patient (SS patients, n=3). The lines link the two halves of the same 1 
lobules treated with the anti-ICOS blockade or its isotype control. Limit of detection (LD) for 2 
each cytokine is highlighted with a dashed line. ELISA quantification of IL-8 and IL-6 in the 3 
supernatants of minor SG lobules organ culture, treated with an anti-ICOS blockade or its 4 
isotype control, for cytokine levels that reach the Legendplex’ upper detection limit. Statistical 5 
analysis by Wilcoxon t-test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (F) All graphs 6 















Key messages:  1 
What is already known about this subject? 2 
Ø In Sjogren’s Syndrome (SS), germinal centers (GC) forming ectopically in salivary 3 
glands (SG) function as niches for auto-reactive B-cells, which formation believed to 4 
results from the GC B and T-cell interaction. Ectopic GC are associated with evolution to 5 
B cell MALT lymphoma in several studies. 6 
Ø T-follicular-helper (Tfh) and recently described pathogenic peripheral-helper T-cells 7 
(Tph) are key mediators in (autoreactive) B-cell differentiation through ICOS-ICOS-L 8 
interaction and IL-21 production, but their relevance has not been investigated in SS 9 
ectopic GC reaction and MALT lymphoma. 10 
What does this study add? 11 
Ø Tfh and Tph-cells are enriched in both SS peripheral blood and SG with GC, invariably 12 
express ICOS, represent the main source of IL-21 and frequently co-express IL-21/IFN-γ, 13 
especially in parotid MALT-lymphoma. 14 
Ø ICOS blockade in ex vivo SG organ cultures significantly reduced the production of IL-15 
21 and inflammatory cytokines IL-6, IL-8, and TNF-α.  16 
How might this impact on clinical practice or future developments? 17 
Ø Tfh and Tph-cells, IL-21 and the ICOS co-stimulatory pathway can be consider 18 
biomarkers of ectopic GC, may be used for patient stratification and represent exploitable 19 
therapeutic targets in SS patients. 20 
 21 
 22 
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are driving the upregulation of this signature in ELS+ patients.
• The Tfh signature show evidence of bimodality across all groups (bottom right);
Tfh-high patients may represent a responder group for Tfh-inhibiting therapies.











































































1way ANOVA-multiple comparison (non parametric test):











































































































































1way ANOVA-multiple comparison (non parametric test):
































































































































































         NSCS            ELS-             ELS+         NSCS          ELS-            ELS+
   
   














   
   







































ns **** **** ns
****
**
   















        NSCS            ELS-            ELS+
ns *** **
C D E
L M N O











































































































































r = p =0.6888 ****
IL-21 vs. BAFF













r = p =0.2622 *
IL-21 vs. AID













r = p =0.523 ****
IL-21 vs. Pax5




























r = p =0.1745 ns
A B
         NSCS           ELS-            ELS+          NSCS           ELS-            ELS+          NSCS           ELS-            ELS+          NSCS           ELS-            ELS+































































































































































































































































































































1way ANOVA-multiple comparison (non parametric test):
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Figure S1. Histological grading and ELS classification of labial SG 
The immune cell type and the degree of infiltration of SG biopsies were assessed by IHC staining 
for T cells (CD3), B cells (CD20), the presence of follicular dendritic cell (FDC) network (CD21) 
and plasma cells (CD138). The degree of infiltration of each immune cell type was scored using a 
semi-quantitative score (0 to 3) and further classified in ELS+ or ELS-. The histological 
identification of ELS in the labial SG biopsies is defined as at least one infiltrate with clear B/T 
cell segregation and presence of FDC, suggestive of germinal center presence. 






























Figure S2. Frequency and cytokines production of circulating Tfh cells, in peripheral blood 
of SS and NSCS patients.  
(A) ELISA quantification of IL-21 serum level (pg/mL) in NSCS (n=37) and SS cohort segregated for ELS 
presence, ELS- (n=18), ELS+ (n=18). Statistical analysis by Kruskal-Wallis-test with Dunn’s post-test 
correction for multiple comparisons. (B) Flow-cytometry gating strategy for circulating T helper 
compartment focusing on Tfh cells (identified as CD4+CD25-Foxp3-CXCR5+ICOS+PD-1+) and 
their cytokines production. Regulatory markers CD25 and Foxp3 were included in the gating 
strategy to exclude Treg (CD4+CD25+Foxp3+) and T-follicular regulatory cells 
(CD4+CD25+Foxp3+CXCR5+ICOS+PD-1+). FMO have been used to define threshold positivity. 
(C) CXCR5+CD4+ cell frequency, as percentage of CD4+ T-cells, based on flow-cytometry 
analysis of PBMC from NSCS (n=10) and SS (n=42). (D) Frequency of CD4+ and CD8+  T cells 
as percentage of lymphocytes gate, identified on the basis of physical parameters (SSC-A and 
FSC-A), based on flow-cytometry analysis of PBMC from NSCS (white dots, n=10) and SS (dark 
grey dots, n=42). (E) Representative flow-cytometry dot plots for Tfh-cell subsets identified on 
the basis of ICOS and PD-1 expression. Frequency of PD-1+ICOS+ Tfh cells, as percentage of 
CXCR5+CD4+ cells in SS cohort segregated on basis of positivity for Ro (F) and La (G) auto-
antibodies. (H) Distribution of IFN-γ producing ICOS+PD-1+CXCR5+CD4+ cells segregated on 
basis of positivity for Ro auto-antibodies. Spearman correlation analysis between frequency of 
PD-1+ICOS+ Tfh cells, as percentage of CXCR5+CD4+ cells, and C4 (I), IgG (J) and SG focus 
score (K). (L) Frequency of CXCR5+CD4+ cells, as percentage of CD4+ cells in SS cohort 
segregated on basis of ELS presence in the SG biopsies. (M) Representative flow-cytometry dot 
plots for Tfh-cells subsets identified on the basis of ICOS and PD-1 expression in SS cohort 
segregated for ELS presence. (O) Frequencies distribution of Tfh-cell subsets, identified on the 
basis of ICOS and PD-1 as percentage of CD4+ cells, in NSCS (white dots, n=10) and SS (dark 
grey dots, n=42) and (P) within SS cohort segregated for ELS presence [ELS-, light grey dots 
(n=17), ELS+, dark grey dots (n=25)]. All graphs represent mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. Abbreviations: Non Specific Chronic Sialoadenitis (NSCS), 





































Figure S3. Cytokines production by T helper (CD4+) compartment in human tonsil. The pie 
chart show the average frequencies of the main cytokines produced by T helper cells, as percentage 
of CD4+ T cells, in human tonsil (n=1). Representative flow-cytometry dot plots showing the 
cytokines production, gated on CD4+ T cells. 
 
 
Supplementary Figure 4 
 
Figure S4. Positive control for IL-21 RNA fluorescence in situ hybridization (FISH). 
Sjogren’s syndrome minor salivary gland section stained with #310451 RNAscope Positive Cont 
Probe Hs-POLR2A, as positive control for IL-21 RNA (FISH).  
 
 Table S1: Antibodies used for immunohistochemistry (IHC) and immunofluorescence (IF) 














































































































Antigen Conjugation Clone Species Manufacturer Dilution 
CD14 BV510 M5E2 Mouse IgG2a, κ Biolegend 1:40 
CD19 BV510 HIB19 Mouse IgG1, κ Biolegend 1:100 
CD56 BV510 HCD56 Mouse IgG1, κ Biolegend 1:50 
CD4 PEDazzle 594 RPA-T4 Mouse IgG1, κ Biolegend 1:300 
CD8 APC Cy7 SK1 Mouse IgG1, κ Biolegend 1:40 
CXCR5 BV605 J252D4 Mouse IgG1, κ Biolegend 1:160 




PD-1 PerCp/Cy5.5 EH12.2H7 Mouse IgG1, κ Biolegend 1:80 
CD25 BV650 BC96 Mouse IgG1, κ Biolegend 1:80 
Foxp3 PE 150D Mouse IgG1, κ Biolegend 1:20 
IL-17A BV711 BL168 Mouse IgG1, κ Biolegend 1:20 




3A3-N2 Mouse IgG1, κ 
Biolegend 
1:40 




JES3-9D7 Rat IgG1, κ 
Biolegend 
1:20 
Table S3: Genes used for gene signature in Gene Set Variation Analysis 
Gene signature Genes 
Bcell CD22, FCRLA, MS4A1, VPREB3, TCL1A, EBF1, FCRL1, BANK1 
PlasmaCell IGHA1, TNFRSF17, IGKV4-1, IGKC, IGJ 
Total_CD19+ IGHM, LOC283663, BANK1, MS4A1, FCRLA, FAM129C, CD19, 
CD22, EBF1,IGHG1, VPREB3, TCL1A 
IFN21 EPSTI1, HERC5, IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT3, ISG15, 
LAMP3, LY6E, MX1, OAS1, OAS2, OAS3, PLSCR1, RSAD2, RTP4, 
SIGLEC1, USP18, SPATS2L 
CD4_T_Cell RCAN3, PLEKHB1, BCL11B, GLTSCR2, RPL22, BAG3, RPL3P7, 
STMN3, RPL3, LTBP3, FAM102A, LOC439949, TCF7, GPRASP1, 
TRAC, SELM, RPL10A, NMT2 
T_EFFECTOR CD8A, CXCL10, CXCL9, EOMES, GZMA, GZMB, IFNG, TBX21 
TH1 CXCL10, CXCL9, IFNG, IL12A, TBX21 
TH2 GATA3, IL13, IL4, IL4R 
Tfh_markers CXCR5, ICOS, PDCD1, SH2D1A 
T_REG CCR7, FOXP3, IL10, IL2RA, ITGB2, TFRC, TGFB1 
Total_CD8 CD8A, CD8B, KLRK1, LCK, CD2, ARL4C, ZAP70, IL32, ZNF827, 
ITK, SLC38A1, C6orf190, IL23A 
MONOCYTES CPVL, ASGR1, CLEC10A, RASSF4, PEA15, TGFBI, LY86, ASGR2, 
DPYSL2, CCDC88A, MYCL1, SLC46A2, PLXNB2, CCR2, VCAN, 
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